For research use only. Not for therapeutic Use.
AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs)[1].
NP-12 TFA displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions [1].
NP-12 TFA rescues the proliferation in the mouse splenocyte assay system with average EC50 values of 17 nM and 16.6 nM against rmPD-L1 and rmPD-L2 respectively [1].
NP-12 TFA is also able to significantly rescue recombinant human PD-L1 and PD-L2 mediated inhibition of in vitro human PBMC proliferation, with average EC50 values of 63.3 nM and 44.1 nM against PD-L1 and PD-L2 respectively [1].
Catalog Number | I046158 |
Molecular Formula | C142H226N40O48.C2HF3O2 |
Purity | ≥95% |
Reference | [1]. Sasikumar PG, et al. A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy. Mol Cancer Ther. 2019 Jun;18(6):1081-1091. |